Department of Liver Surgery, Peking Union Medical College Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2426869. doi: 10.1080/21645515.2024.2426869. Epub 2024 Nov 13.
Cellular immunotherapy has shown considerable potential for the treatment of primary liver cancer (PLC), particularly hepatocellular carcinoma (HCC), although it is in the early stages of development. This study used bibliometric methods to delineate the evolution of research on cellular immunotherapy for PLC. Data were sourced from the Web of Science Core Collection (WoSCC) on April 22, 2024. Using the "Bibliometrix" R package, we examined primary bibliometric features, collaboration frequency between countries, and article output of the journals. Furthermore, we employed VOSviewer for coauthorship analysis and visualization and CiteSpace to assess keyword co-occurrence, as well as to spotlight keywords and references with the strongest citation bursts. Our analysis encompassed 492 publications focused on PLC and cellular immunotherapy, and we pinpointed China, Japan, and the USA as the foremost contributing nations and identified "" as the journal with the most contributions in this area. Sun Yat-sen University emerged as the institution with the most significant output, and Li Zonghai authored the greatest number of leading articles. Prominent keywords that displayed a notable citation burst in the later years included "chimeric antigen receptor," "combination therapy", "CAR-T cells," "TCR-T cells," and "liver transplantation." This bibliometric study outlined a foundational knowledge framework, surveyed over three decades of research on cellular immunotherapy for PLC, and revealed the key players and trends, thereby offering a thorough understanding of the field, especially in relation to HCC.
细胞免疫疗法在原发性肝癌(PLC)治疗中显示出相当大的潜力,特别是肝细胞癌(HCC),尽管它仍处于早期发展阶段。本研究采用文献计量学方法描绘了 PLC 细胞免疫治疗研究的演变。数据于 2024 年 4 月 22 日从 Web of Science 核心合集(WoSCC)中获取。使用“Bibliometrix”R 包,我们检查了主要的文献计量特征、国家之间的合作频率以及期刊的文章产出。此外,我们使用 VOSviewer 进行合著分析和可视化,并使用 CiteSpace 评估关键词共现,以及突出具有最强引文爆发的关键词和参考文献。我们的分析涵盖了 492 篇聚焦于 PLC 和细胞免疫治疗的出版物,并确定了中国、日本和美国是主要的贡献国家,并确定“Cellular Immunology”是该领域贡献最多的期刊。中山大学是产出最多的机构,而李忠海发表的主要文章最多。近年来表现出显著引文爆发的突出关键词包括“嵌合抗原受体”、“联合治疗”、“CAR-T 细胞”、“TCR-T 细胞”和“肝移植”。这项文献计量研究概述了一个基础知识框架,调查了三十多年来 PLC 细胞免疫治疗的研究,并揭示了关键参与者和趋势,从而全面了解该领域,特别是与 HCC 相关的领域。
Hum Vaccin Immunother. 2024-12-31
Front Immunol. 2023
World J Gastroenterol. 2024-3-7
Front Biosci (Landmark Ed). 2022-8-31
J Cancer Res Clin Oncol. 2024-6-24
J Natl Cancer Cent. 2024-2-2
Am J Physiol Cell Physiol. 2024-7-1
Int J Mol Sci. 2024-1-23
Crit Rev Oncog. 2023
Liver Cancer. 2023-4-5
Support Care Cancer. 2023-10-11